We reviewed the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout with interest. First, we want to commend the committee for the excellent job they did in updating the guidelines. We noted the commitment to evidence- based medicine and also that the indications for starting urate-lowering therapy (ULT) have been expanded to consider patients with infrequent gout flares or a first gout flare if they also have moderate to severe chronic kidney disease (CKD stage ≥ 3), marked hyperuricemia (serum urate (SU) > 9 mg/dl) or kidney stones.
|Original language||English (US)|
|Journal||Arthritis Care and Research|
|State||E-pub ahead of print - Jul 23 2020|